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Abstract
The Ca
2+-activated Cl
2 channel TMEM16A is involved in epithelial fluid secretion, smooth muscle contraction and
neurosensory signaling. We identified a Thai herbal antidiarrheal formulation that inhibited TMEM16A Cl
2 conductance.
C18-reversed-phase HPLC fractionation of the herbal formulation revealed .98% of TMEM16A inhibition activity in one out
of approximately 20 distinct peaks. The purified, active compound was identified as eugenol (4-allyl-2-methoxyphenol), the
major component of clove oil. Eugenol fully inhibited TMEM16A Cl
2 conductance with single-site IC50,150 mM. Eugenol
inhibition of TMEM16A in interstitial cells of Cajal produced strong inhibition of intestinal contraction in mouse ileal
segments. TMEM16A Cl
2 channel inhibition adds to the list of eugenol molecular targets and may account for some of its
biological activities.
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Introduction
Intestinal fluid secretion in secretory diarrheas involves Cl
2
movement from the blood to the intestinal lumen through Cl
2
channels on the enterocyte apical plasma membrane. These Cl
2
channels include a cAMP-gated channel, CFTR (cystic fibrosis
transmembrane conductance regulator), and Ca
2+-activated Cl
2
channels (CaCCs), one of which has been identified as TMEM16A
[1,2]. While CFTR probably provides the primary route for Cl
2
transport in enterotoxin-mediated secretory diarrheas such as
cholera, CaCCs are likely involved as well and may provide the
primary route for Cl
2 transport in some viral, drug-induced and
AIDS-related diarrheas [3–5].
TMEM16A (alternative name, ANO1) has been identified as a
CaCC that is broadly expressed in tracheal, intestinal and
glandular epithelia, smooth muscle cells, and gastrointestinal
interstitial cells of Cajal, where it is involved in epithelial fluid
secretion, smooth muscle contraction and gastrointestinal motility
[6–8]. TMEM16A is also expressed in various tumors, where it
may play a role in tumor cell proliferation [6]. We previously
identified, by high-throughput screening, several small-molecule
inhibitors and activators of TMEM16A Cl
2 conductance [9,10],
which have potential therapeutic value in cystic fibrosis, dry
mouth, gastric hypomotility (activators), secretory diarrhea, pain
and tumor growth (inhibitors). We also discovered that gallotan-
nin-containing red wines and green teas inhibit CaCC/
TMEM16A activity, which may account for their reported
beneficial effects in cardiovascular disease and secretory diarrheas
[11].
Here, we identified an antidiarrheal herbal medicinal formula-
tion with TMEM16A inhibition activity, which, upon purification
and characterization, was attributed to eugenol, a major
component of clove oil [12]. Despite its small molecular size,
eugenol has been reported to have a wide range of biological
activities. Eugenol is an oxygen radical scavenger and can prevent
chemically induced organ damage by reducing lipid peroxidation
[13–15]. Eugenol slows the growth of some tumors by reducing
cell proliferation and increasing apoptosis [16,17]. Eugenol also
inhibits cyclooxygenase, inhibiting the biosynthesis of prostanoids,
which cause pain, inflammation and carcinogenesis [18]. Here, we
report a new activity for eugenol – Cl
2 channel inhibition – that
may account for some of its biological activities including analgesia
and tumor suppression.
Results
TMEM16A inhibition by a Thai herbal formulation
Testing of eight Asian antidiarrheal remedies revealed inhibi-
tion of intestinal CaCC/TMEM16A by a Thai herbal formulation
(Fig. 1A), which consists of a dark brown, pungent liquid
containing a small amount of precipitate. Short-circuit current
measurement in Fig. 1B shows inhibition of ATP-stimulated
CaCC activity in T84 human colonic epithelial cells, with 50%
inhibition at ,0.05% (1:2000 dilution) of the original formulation.
The CaCC inhibitor tannic acid completely inhibited Cl
2 current.
Fig. 1C shows inhibition of TMEM16A Cl
2 current in Eact-
simulated FRT cells expressing human TMEM16A. Eact is a
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inhibitor T16Ainh-A01 [9] completely inhibited Cl
2 current.
HPLC fractionation and structure determination
Fig. 2A shows HPLC fractionation of the Thai herbal
formulation. There were approximately 20 distinct peaks in the
chromatogram overlying a broad peak. Each of the 53 collected
fractions was tested for inhibition of TMEM16A using a plate-
reader assay with FRT cells expressing the I
2-sensitive fluorescent
protein YFP-H148Q/I152L/F46L and human TMEM16A. As
diagrammed in Fig. 2B (left) I
2 addition reduced cellular
fluorescence following TMEM16A activation by ATP. Fig. 2B
(right) shows that fraction 30 fully inhibited TMEM16A-mediated
I
2 influx, whereas the other fractions had little effect. Fig. 2A
shows an expanded view of fraction 30.
Fraction 30 was resolved using a second HPLC column,
showing a single peak (Fig. 3A). High-resolution mass spectrom-
etry of the purified material gave the molecular size (164 Da) and
known fragmentation pattern of eugenol (Fig. 2B). In order to
verify eugenol as compound identity, we obtained
1H,
13C,
COSY, HMQC and HMBC NMR spectra because some
structural isomers of eugenol, such as chavibetol, have nearly
identical mass spectrometric patterns. NMR spectra of purified
fraction 30 were identical to commercial eugenol, as was
TMEM16A inhibition potency, confirming compound identity.
The concentration of eugenol in the original Thai herbal
formulation was ,200 mM as measured by HPLC against
eugenol standards.
Biological studies
Fig. 4A shows short-circuit current in TMEM16A-expressing
FRT cells in which the basolateral membrane was permeabilized
with amphotericin B and a transepithelial Cl
2 gradient was
applied. Addition of eugenol 5 min prior to activation of
TMEM16A by 1 mM ionomycin produced concentration-depen-
dent inhibition of Cl
2 current. Fig. 4B showed inhibition of Eact-
stimulated TMEM16A Cl
2 current by increasing eugenol
concentrations. Concentration-inhibition data in Fig. 4C gave a
fitted IC50 of 154 mM. Eugenol did not inhibit cytoplasmic Ca
2+ in
response to ATP (Fig. 4D). Similar results were obtained for Ca
2+
elevation following ionomycin treatment (not shown). Whole-cell
patch-clamp analysis was done to investigate the engenol
inhibition mechanism (Fig. 4E). Application of 150 mM eugenol
inhibited TMEM16A chloride current (induced by 5 mME act)a t
all voltages, indicating a voltage-independent block mechanism.
The Cl
2 channel selectivity of eugenol inhibition was studied.
Many inhibitors of CaCCs are non-selective Cl
2 channel
inhibitors that also inhibit CFTR [19]. Fig. 5A shows that
eugenol, which inhibits TMEM16A by .95% at 1 mM, had little
effect on CFTR Cl
2 conductance. To determine whether the site
of action of eugenol on TMEM16A might overlap with that of the
Figure 1. Inhibition of Ca
2+-activated Cl
2 channels by a Thai herbal formulation. A. Thai herbal medicine for diarrhea. B. Short-circuit
measurement in T84 cells. Representative current trace (dark curve) shows inhibition of ATP (100 mM)-stimulated native CaCC Cl
2 current by the Thai
herbal formulation. Current in the control study (gray curve) without the herbal formulation was inhibited with 100 mM tannic acid. C. Current
measurement in TMEM16A-transfected FRT cells shows inhibition of Eact (10 mM, a TMEM16A activator)-stimulated TMEM16A Cl
2 current by the Thai
herbal formulation (dark curve). Control study (gray curve) without the herbal formulation shows that 10 mM T16Ainh-A01 (TMEM16A-selective
inhibitor) totally inhibited the current.
doi:10.1371/journal.pone.0038030.g001
Figure 2. Fractionation of Thai herbal formulation. A. HPLC
fractionation showing the chromatogram at 280 nm absorbance.
Vertical lines at the top show 53 collected fraction with expanded
view of fraction 30 shown at the right. B. (left) Principle of cell-based
fluorescence plate-reader assay. TMEM16A-facilitated I
2 influx was
measured from the kinetics of decreasing YFP-H148Q/I152L/F46L
fluorescence in response to addition of I
2 solution containing the
P2Y agonist ATP, which elevates cytoplasmic Ca
2+ level. (right)
Inhibition by HPLC fractions shows the majority of activity resides in
fraction 30.
doi:10.1371/journal.pone.0038030.g002
Eugenol Inhibits TMEM16A Cl
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tor T16Ainh-A01, we studied whether pre-added T16Ainh-A01
affected the potency of eugenol (Fig. 5B). Fig. 5C shows that pre-
treatment with 1 mM T16Ainh-A01 increased the eugenol IC50
from ,150 mM to 280 mM, suggesting partial overlap in their
binding sites.
TMEM16A is expressed in interstitial cells of Cajal, the
pacemaker cells that control smooth muscle contraction in
stomach and intestine [8]. We previously showed that inhibition
of TMEM16A by T16Ainh-A01 inhibited mouse intestinal smooth
muscle contraction [10]. Eugenol was tested in mouse ileum ex
vivo. Fig. 6A shows considerable constitutive activity of mouse ileal
muscle segments at baseline, with large, spontaneous intestinal
contractions that were inhibited by eugenol in a dose-dependent
manner. Eugenol had a small effect on contraction frequency
(Fig. 6B), but a more marked effect on resting and maximal tone
(Fig. 6C). Fig. 6D shows eugenol inhibition of ileal contractions
following activation by Eact, in which atropine was added initially
to reduce basal constitutive activity.
Structure-activity analysis
Eugenol contains three functional groups - hydroxyl, methoxy
and allyl groups - on a single phenyl ring. Table S1 summarizes
TMEM16A inhibition activity of eugenol (compound 1) and
commercially available analogs (compounds 2–11) at 200 mM. A
series of hydroxyl and methoxy combinations at R
1,R
2 and R
3
were tested, as well as different aliphatic chains at R
4. Inhibition
activity required a large hydrophobic group at R
4. Short
hydrocarbon chains (compounds 2, 3 and 6) or a hydrophilic
chain (compound 8) reduced inhibition activity. The terminal
double bond of allyl group in eugenol is not required the activity
(compounds 4, 5 and 7).
Discussion
Eugenol is an aromatic molecule found in various plants and
essential oils. While it is found in basil, cinnamon, Japanese star
anise, lemon balm and dill, eugenol is best known as a major
component in clove (Syzygium aromaticum), making up 85–90% of
clove leaf oil, 80–85% of clove bud oil, and 87–92% of clove stem
oil [12]. The first biological action of eugenol, antibacterial
activity, was reported in 1947 [20]. Subsequently, numerous
studies have reported eugenol effects on immune, reproductive,
cardiovascular, gastric, nervous and urinary systems [21]. Because
of its wide range of activities and its natural abundance, eugenol
has become a widely available dietary supplement.
Though eugenol inhibition of Cl
2 channels has not been
reported previously, eugenol has been reported to modulate the
activity of several cation channels in neurons, muscle cells and
epithelial cells. There is evidence that the well-known analgesic
property of eugenol in dentistry, where eugenol is applied topically
[22], is related to inhibition of Na
+ [23], K
+ [24] and Ca
2+ [25]
channels. A recent report shows that inhibition of TMEM16A in
rat sensory neurons block bradykinin-induced nociceptive signals
[26]. TMEM16A inhibition by eugenol may thus account, in part,
for its analgesic effects when applied topically.
Yeon et al. [27] reported that eugenol inhibited hyperpolariza-
tion-activated cyclic nucleotide-gated Na
+ and K
+ channels in
trigeminal ganglion neurons with IC50 of 157 mM. In general,
IC50 for eugenol activities are 100 mM or greater, which is
probably related to its small molecular size. IC50 values were
,300 mM for inhibition of Ca
2+ current in cardiac myocytes [28],
and ,600 mM for inhibition of tracheal smooth muscle contrac-
tion [29]. The concentration of engenol in blood is much lower
than typical IC50 values, even with high dose oral administration.
Lionnet et al. [30] reported eugenol concentrations in rat after oral
administration (40 mg/kg) of 0.6 mM in serum and 2.8 mMi n
brain and spinal cord. A similar study in rats revealed a serum
concentration of 1.5 mM [31]. Higher serum concentrations of
eugenol of 180 mM were found following intravenous administra-
tion [32], suggesting limited oral bioavailability and/or first-pass
hepatic metabolism. The glucuronide conjugate of eugenol and
eugenol sulfate have been detected in blood and urine [32,33].
We found here an IC50 of ,150 mM for eugenol for the
inhibition of TMEM16A Cl
2 current in cells and inhibition of
intestinal smooth muscle contraction. The Thai herbal formula-
tion contains ,200 mM eugenol. With a recommended oral dose
of the herbal formulation of 5–10 mL and a typical intestine fluid
volume of several liters, the intestinal eugenol concentration
should be in the range of several hundred micromolar, where it is
predicted to inhibit TMEM16A.
In conclusion, we found that eugenol is an inhibitor of
TMEM16A Cl
2 channels, adding to the list of eugenol molecular
targets and potentially accounting for its antidiarrheal and
analgesic activities.
Materials and Methods
Ethics Statement
Protocols were approved by the University of California San
Francisco Committee on Animal Research.
Cell lines and materials
FRT cells stably expressing human TMEM16A and the halide
sensor YFP-H148Q/I152L/F46L were generated as described
[9]. Cells were plated in 96-well black-walled microplates (Corning
Inc., Corning, NY) at a density of 20,000 cells per well in Coon’s
Figure 3. Identification of purified active fraction as eugenol. A.
HPLC of fraction 30, showing a single peak. B. High-resolution mass
spectra of purified fraction 30. Inset: Structure of eugenol.
doi:10.1371/journal.pone.0038030.g003
Eugenol Inhibits TMEM16A Cl
2 Channel
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e38030Figure 4. TMEM16A inhibition by eugenol. A. Short-circuit current measured in TMEM16A-expressing FRT cells in the presence of a
transepithelial Cl
2 gradient. Indicated concentrations of eugenol were added 10 min prior to TMEM16A activation by 1 mM ionomycin. B. Short-circuit
current measured after TMEM16A activation by 10 mME act, followed by indicated concentrations of eugenol. C. Eugenol concentration inhibition data
from measurements in B (mean 6 S.E., n=4). D. Eugenol does not inhibit cytoplasmic Ca
2+ elevation in response to ATP as shown by Fluo-4
fluorescence. Cells were incubated with eugenol for 10 min prior to measurements. E. Whole-cell TMEM16A current recorded at a holding potential of
0 mV, and pulsing to voltages between 6 80 mV (in steps of 20 mV) in the absence and presence of 150 mM eugenol (left). TMEM16A was activated
by 5 mME act. Current/voltage (I/V) plot of mean currents at the middle of each voltage pulse (center). Summary of current density data measured at
+80 mV (right, mean 6 S.E., n=5).
doi:10.1371/journal.pone.0038030.g004
Figure 5. Eugenol selectivity and binding. A. CFTR Cl
2 current was measured in FRT cells expressing wild type CFTR-expressing in the presence
of a transepithelial Cl
2 gradient and after basolateral membrane permeabilization. CFTR Cl
2 current was stimulated by forskolin (20 mM), followed by
eugenol addition. CFTR Cl
2 current was completely inhibited by CFTRinh-172 (10 mM). B. Investigation of possible synergy/competition of eugenol
with T16Ainh-A01. T16Ainh-A01 (1 mM) was added to inhibit TMEM16A Cl
2 current by ,50% followed by indicated concentrations of eugenol. C.
Eugenol concentration inhibition data from measurements in B (mean 6 S.E., n=3–4).
doi:10.1371/journal.pone.0038030.g005
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2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL strep-
tomycin. T84 cells were cultured in DMEM/Ham’s F-12 (1:1)
medium containing 10% FBS, 100 U/ml penicillin and 100 mg/
ml streptomycin. A commercially available Thai herbal formula-
tion (Krisanaklan, Osotspa Inc., Bangkapi, Thailand) consists of an
ethanol/water (54:46) extract in which each 100 mL was obtained
from 10 g of Aquilaria crassna bark, 33.3 g of clove flower bud, 2 g
of Terminalia triptera Stapf bark and 4.8 g of camphor flower bud.
HPLC grade solvents were purchased from Fisher Scientific
(Fairlawn, VA) and EMD Chemical Inc. (Philadelphia, PA).
Eugenol and eugenol analog 2 were purchased from Sigma-
Aldrich (St. Louis, MO). Other eugenol analogs were purchased
from Fisher Scientific (Pittsburgh, PA).
Plate-reader fluorescence assay of I
2 influx
YFP fluorescence measurements in TMEM16A expressing FRT
cells were carried out on a fluorescence plate reader (Optima;
BMG Labtech, Durham, NC) equipped with dual syringe pumps
and 500610 nm excitation and 535615 nm emission filters as
described [11]. Each well of a 96-well plate was washed 3 times
with PBS (200 mL/wash). The fractions from the Thai herbal
formulation (2 mL) and 100 mL PBS were added to each well. After
10 min incubation, each well was assayed individually for
TMEM16A-mediated I
2 influx by recording fluorescence contin-
uously (400 ms per point) for 2 s (baseline), followed by addition of
100 mL of a 140 mM I
2 solution containing 200 mM ATP. The
initial rate of I
2 influx was computed from fluorescence data by
non-linear regression.
Short-circuit current
Snapwell inserts containing TMEM16A-expressing FRT cells
or T84 cells were mounted in Ussing chambers (Physiologic
Instruments, San Diego, CA). Activators and inhibitors (herbal
formulation, eugenol, ionomycin, tannic acid, forskolin, CFTRinh-
172, ATP, Eact, T16Ainh-A01) were added to the apical solution
and an equal volume of vehicle was added at the same time to the
basolateral solution. Symmetrical HCO3
2-buffered solutions were
used for T84 cells. For FRT cells, the hemichambers were filled
with a half-Cl
2 solution (apical) and the HCO3
2-buffered solution
(basolateral), and the basolateral membrane was permeabilized
with 250 mg/mL amphotericin B. Cells were bathed for a 10 min
stabilization period and aerated with 95% O2/5% CO2 at 37uCo r
room temperature. Short-circuit current was measured using an
EVC4000 Multi-Channel V/I Clamp (World Precision Instru-
ments, Sarasota, FL).
Patch-clamp
Whole-cell recordings were made at room temperature on
TMEM16A-expressing FRT cells as described [9]. The pipette
solution contained (in mM): 130 CsCl, 0.5 EGTA, 1 MgCl2,1
Tris-ATP, and10 HEPES (pH 7.2). The bath solution contained
(in mM): 140 NMDG-Cl, 1 CaCl2, 1 MgCl2, 10 glucose and 10
HEPES (pH 7.4). TMEM16A was activated by 5 mME act and
then inhibited by 150 mM eugenol. Whole-cell currents were
elicited by applying hyperpolarizing and depolarizing voltage
pulses from a holding potential of 0 mV to potentials between
280 mV and +80 mV in 20 mV steps. Currents were digitized,
filtered at 5 kHz, and sampled at 1 kHz.
Figure 6. Eugenol inhibits intestinal smooth muscle contraction. A. Representative traces from mouse ileal segments showing eugenol
inhibition of contractions. B. Eugenol effect on relative contraction frequency (mean 6 S.E., n=4, * P,0.05). C. Eugenol effect on resting and
maximum tone (mean 6 S.E., n=4, * P,0.05). D. Eugenol inhibition of ileal contraction after stimulation by TMEM16A activator Eact. Representative of
3 experiments.
doi:10.1371/journal.pone.0038030.g006
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2+ measurement
FRT cells in 96-well plates were loaded with Fluo-4 NW
(Invitrogen, Carlsbad, CA) at 48 h after plating. Fluo-4 fluores-
cence was measured continuously using a FLUOstar Optima
fluorescence plate reader (BMG Labtechnologies) equipped with
syringe pump for addition of ATP.
Intestinal smooth muscle contraction
Wild type CD1 mice (age 8–10 weeks) were killed by avertin
overdose (200 mg/kg). The ileum was removed and washed with
ice-cold HCO3
2-buffered solution. The ends of the ileal segments
were tied with silk thread and connected to a force transducer.
Ileal segments were equilibrated for 60 min with a resting force of
,1 mN, with changes of the bathing solution every 15 min.
Tension was monitored continuously with a fixed-range precision
force transducer (TSD, 125 C; Biopac, Goleta, CA) connected to a
differential amplifier (DA 100B; Biopac). Data were recorded
using MP100, Biopac digital acquisition system and analyzed using
Acknowledge 3.5.7 software.
High performance liquid chromatography (HLPC)
Fractionation was performed on an AKTAexplore 10 system
(GE Healthcare Life Science, Piscataway, NJ) equipped with a
C18 reversed-phase column (Varian Pursuit XRs, 250610 mm,
5 mm particle size, Waldbronn, Germany). After 1 mL of the
formulation was injected, the gradient was developed with mobile
phase A (0.1% formic acid in water) and mobile phase B
(methanol) at 5 mL/min flow rate. The mobile phase was 100% A
for 4 min, followed by a linear decrease to 1% A over 40 min, and
then 1% A for 40 min. Absorption was recorded at 280 nm. Total
eluent was collected in 53 fractions (8 mL/fraction). The purity of
the active component, as determined by plate reader assay, was
verified on a separate C18 column (Pharmacia Biotech,
25064.6 mm, 5 mm, Uppsala, Sweden). After 100 mL was
injected, the gradient was developed with mobile phase A and
mobile phase C (acetonitrile) at 1 mL/min flow rate.
Structure characterization
NMR spectra were obtained on a Bruker 300 MHz instrument
(Madison, WI). HRMS was done at the High Resolution Mass
Spectrometry Facility at the University of California, Riverside.
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